This combination immunotherapy required a T cell vaccine, tumor-targeting-antibody, recombinant IL-2, and anti-PD-1 blockade, which induced recruitment of tumor infiltrating immune cells and production of intratumoral proinflammatory cytokines in a genetically engineered murine melanoma [88]. Here, IL2 is linked to neoplasm.